Stay updated with breaking news from Toby Maher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The world's first-in-class candidate substance against idiopathic pulmonary fibrosis, 'Bersiposocin' (DWN12088), which is under development...
A clinical trial found that rituximab and cyclophosphamide had similar outcomes for interstitial lung disease associated with connective tissue disorders.
Drug targeting B cells as effective as broad-spectrum immunosuppressant in lung disease
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),...
The new results show stabilization of disease already from week 6 and confirm the unprecedented increase in lung function over timeVicore will accelerate clinical developmentInvitation to conference